|
|
Good Morning Everyone,
TXG resting at a key resistance/support point yet to be determined. We did have a short break above followed by a retrace.
As of October 23, 2025, 10x Genomics (TXG) stock has a "Hold" consensus rating based on analysis from 19 brokerage firms
. The average 12-month price target is approximately $13.65, representing a potential upside of 2.31% from the last closing price. However, some analysts have varying forecasts, with price targets ranging from a low of $6.50 to a high of $17.00.
Recent analyst actions and financial news include:
On October 23, 2025, MarketWatch noted a sharp decline in shares, attributed to a revenue warning that prompted a downgrade from a BofA Securities analyst.
One day earlier, on October 22, Simply Wall St reported that the stock was down, potentially signaling an opportunity, though it advised scrutiny.
In August and September of 2025, several firms, including Piper Sandler, Morgan Stanley, and Barclays, adjusted their price targets.
A S
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
